SCHEMBL5715340

SCHEMBL5715340

Cn1ccnc1SCc1ccc(OC(=O)N2CCN(c3ccccn3)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 8/20 0.51
NPSR1 Q6W5P4 2/20 0.51
HPGD P15428 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ALDH1A1 P00352 7/20 0.50
TSHR P16473 5/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
CYP3A4 P08684 3/20 0.50
CYP1A2 P05177 3/20 0.50
CYP2C9 P11712 3/20 0.50
CYP2C19 P33261 3/20 0.50
MAPK1 P28482 3/20 0.50
KDM4E B2RXH2 7/20 0.46
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
HDAC1 Q13547 1/20 0.45
CYP2D6 P10635 1/20 0.44
KMT2A Q03164 2/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715206 0.91 HSD17B10 (0.49) HSD17B10NPSR1HPGDL3MBTL1ALDH1A1
SCHEMBL5716251 0.88 SMN1; SMN2 (0.47) HSD17B10NPSR1HPGDL3MBTL1ALDH1A1
SCHEMBL5715238 0.87 SMN1; SMN2 (0.48) HPGDSMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL5715489 0.86 SMN1; SMN2 (0.47) ALDH1A1TSHRSMN1; SMN2CYP1A2CYP2C19
SCHEMBL5715123 0.86 SMN1; SMN2 (0.47) HPGDSMN1; SMN2CYP3A4CYP2C9CYP2C19
SCHEMBL5715041 0.85 SMN1; SMN2 (0.51) HSD17B10HPGDALDH1A1TSHRSMN1; SMN2
SCHEMBL5715039 0.85 SMN1; SMN2 (0.46) HSD17B10NPSR1HPGDL3MBTL1ALDH1A1
SCHEMBL5715380 0.85 KDM4E (0.51) ALDH1A1TSHRSMN1; SMN2MAPK1KDM4E
SCHEMBL5715293 0.84 TP53 (0.49) ALDH1A1SMN1; SMN2KDM4ELMNAHDAC1
SCHEMBL5715776 0.84 SMN1; SMN2 (0.55) HPGDL3MBTL1ALDH1A1SMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC HSD17B10 285/4885NPSR1 1181/4885HPGD 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.